These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 19244124)

  • 1. Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.
    Daouti S; Wang H; Li WH; Higgins B; Kolinsky K; Packman K; Specian A; Kong N; Huby N; Wen Y; Xiang Q; Podlaski FJ; He Y; Fotouhi N; Heimbrook D; Niu H
    Cancer Res; 2009 Mar; 69(5):1924-32. PubMed ID: 19244124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
    Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
    Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models.
    Daouti S; Higgins B; Kolinsky K; Packman K; Wang H; Rizzo C; Moliterni J; Huby N; Fotouhi N; Liu M; Goelzer P; Sandhu HK; Li JK; Railkar A; Heimbrook D; Niu H
    Mol Cancer Ther; 2010 Jan; 9(1):134-44. PubMed ID: 20053779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
    Miller CR; Oliver KE; Farley JH
    Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.
    Mandal R; Becker S; Strebhardt K
    Oncogene; 2016 May; 35(20):2547-61. PubMed ID: 26364606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The biology and clinical development of MEK inhibitors for cancer.
    Luke JJ; Ott PA; Shapiro GI
    Drugs; 2014 Dec; 74(18):2111-28. PubMed ID: 25414119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.
    Senawong T; Phuchareon J; Ohara O; McCormick F; Rauen KA; Tetsu O
    Hum Mol Genet; 2008 Feb; 17(3):419-30. PubMed ID: 17981815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
    Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
    Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
    Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.
    Kim DJ; Lee MH; Reddy K; Li Y; Lim DY; Xie H; Lee SY; Yeom YI; Bode AM; Dong Z
    Carcinogenesis; 2013 May; 34(5):1134-43. PubMed ID: 23354306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERK1/2 can feedback-regulate cellular MEK1/2 levels.
    Hong SK; Wu PK; Karkhanis M; Park JI
    Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.
    Martinelli E; Morgillo F; Troiani T; Ciardiello F
    Cancer Treat Rev; 2017 Feb; 53():61-69. PubMed ID: 28073102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the ERK signaling pathway in cancer therapy.
    Kohno M; Pouyssegur J
    Ann Med; 2006; 38(3):200-11. PubMed ID: 16720434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
    Iverson C; Larson G; Lai C; Yeh LT; Dadson C; Weingarten P; Appleby T; Vo T; Maderna A; Vernier JM; Hamatake R; Miner JN; Quart B
    Cancer Res; 2009 Sep; 69(17):6839-47. PubMed ID: 19706763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p38 MAPK regulates phosphorylation of Bad via PP2A-dependent suppression of the MEK1/2-ERK1/2 survival pathway in TNF-alpha induced endothelial apoptosis.
    Grethe S; Pörn-Ares MI
    Cell Signal; 2006 Apr; 18(4):531-40. PubMed ID: 15972258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.
    Wu PK; Park JI
    Semin Oncol; 2015 Dec; 42(6):849-62. PubMed ID: 26615130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.
    Ishii N; Harada N; Joseph EW; Ohara K; Miura T; Sakamoto H; Matsuda Y; Tomii Y; Tachibana-Kondo Y; Iikura H; Aoki T; Shimma N; Arisawa M; Sowa Y; Poulikakos PI; Rosen N; Aoki Y; Sakai T
    Cancer Res; 2013 Jul; 73(13):4050-4060. PubMed ID: 23667175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.